STOCK TITAN

Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South Korea

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Positive)
Tags

Lipocine Inc. (NASDAQ: LPCN) has entered into a license, development and supply agreement with SPC Korea for exclusive marketing rights of TLANDO® in South Korea. The agreement includes an upfront payment, potential regulatory and sales milestone payments, royalties on net commercial sales, and a supply price arrangement. SPC Korea will be responsible for obtaining regulatory approval in South Korea. This partnership aims to expand TLANDO's global reach and address unmet medical needs in the South Korean market.

Lipocine Inc. (NASDAQ: LPCN) ha stipulato un accordo di licenza, sviluppo e fornitura con SPC Korea per i diritti di marketing esclusivi di TLANDO® in Corea del Sud. L'accordo prevede un pagamento iniziale, potenziali pagamenti per traguardi normativi e di vendita, royalties sulle vendite commerciali nette e un accordo sui prezzi di fornitura. SPC Korea sarà responsabile per l'ottenimento dell'approvazione regolatoria in Corea del Sud. Questa partnership mira ad ampliare la portata globale di TLANDO e a rispondere a esigenze mediche insoddisfatte nel mercato sudcoreano.

Lipocine Inc. (NASDAQ: LPCN) ha firmado un acuerdo de licencia, desarrollo y suministro con SPC Korea para los derechos de marketing exclusivos de TLANDO® en Corea del Sur. El acuerdo incluye un pago inicial, posibles pagos por hitos regulatorios y de ventas, regalías sobre las ventas comerciales netas, y un acuerdo de precios de suministro. SPC Korea será responsable de obtener la aprobación regulatoria en Corea del Sur. Esta asociación tiene como objetivo expandir el alcance global de TLANDO y abordar necesidades médicas insatisfechas en el mercado surcoreano.

리포신 Inc. (NASDAQ: LPCN)은 SPC 코리아와 한국에서의 TLANDO® 독점 마케팅 권리를 위한 라이선스, 개발 및 공급 계약을 체결했습니다. 이 계약에는 초기 지급금, 잠재적인 규제 및 판매 이정표 지급금, 순 상업 판매에 대한 로열티 및 공급 가격 협정이 포함됩니다. SPC 코리아는 한국에서 규제 승인을 받는 책임이 있습니다. 이 파트너십은 TLANDO의 글로벌 확장을 목표로 하며 한국 시장의 충족되지 않은 의료 요구를 해결하는 데 초점을 맞추고 있습니다.

Lipocine Inc. (NASDAQ: LPCN) a conclu un accord de licence, de développement et de fourniture avec SPC Korea pour les droits de marketing exclusifs de TLANDO® en Corée du Sud. L'accord comprend un paiement initial, des paiements potentiels pour des jalons réglementaires et de vente, des redevances sur les ventes commerciales nettes, et un arrangement de prix de fourniture. SPC Korea sera responsable de l'obtention de l'approbation réglementaire en Corée du Sud. Ce partenariat vise à étendre la portée mondiale de TLANDO et à répondre à des besoins médicaux non satisfaits sur le marché sud-coréen.

Lipocine Inc. (NASDAQ: LPCN) hat eine Lizenz-, Entwicklungs- und Liefervereinbarung mit SPC Korea für die exklusiven Vermarktungsrechte von TLANDO® in Südkorea abgeschlossen. Die Vereinbarung umfasst eine Vorauszahlung, potenzielle regulatorische und Verkaufsmeilensteinzahlungen, Lizenzgebühren auf den Nettoumsatz und eine Preisvereinbarung für die Lieferung. SPC Korea ist verantwortlich für die Erlangung der behördlichen Genehmigung in Südkorea. Diese Partnerschaft zielt darauf ab, die globale Reichweite von TLANDO zu erweitern und unerfüllte medizinische Bedürfnisse auf dem südkoreanischen Markt anzugehen.

Positive
  • Secured exclusive licensing agreement for TLANDO in South Korean market
  • Multiple revenue streams: upfront payment, milestone payments, royalties, and supply pricing
  • No development costs as SPC Korea assumes responsibility for regulatory approval
Negative
  • Specific financial terms and potential revenue impact not disclosed

Insights

This licensing deal marks a strategic expansion for TLANDO into South Korea's testosterone replacement therapy market. The agreement includes multiple revenue streams:

  • Upfront payment
  • Regulatory milestone payments
  • Sales-based milestone payments
  • Ongoing royalties
  • Supply pricing revenue
While specific financial terms aren't disclosed, such agreements typically provide meaningful revenue potential for small-cap biotech companies. The deal structure minimizes Lipocine's commercial risk while maintaining upside exposure through royalties and supply pricing. South Korea's pharmaceutical market, valued at approximately $16 billion, presents a significant opportunity for TLANDO, particularly given the country's aging population and increasing focus on men's health treatments.

SALT LAKE CITY, Oct. 31, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced a license, development and supply agreement with to SPC Korea http://spcpharm.co.kr granting exclusive rights to market TLANDO® in South Korea.

Under the terms of the distribution and license agreement, Lipocine will receive an upfront payment and is also eligible to receive certain regulatory and sales milestone payments, including a payment upon regulatory approval of TLANDO in South Korea. Lipocine is entitled to royalties on net commercial sales. Lipocine will supply TLANDO to SPC Korea and will receive a supply price. SPC Korea will assume responsibility for obtaining regulatory approval within the territory.

"We are very pleased to partner TLANDO with SPC Korea," said Dr. Mahesh Patel, President and Chief Executive Officer of Lipocine. "This license agreement represents a strategic opportunity to expand the global reach of TLANDO and to address the significant unmet medical need in South Korea. It underscores Lipocine's commitment to strategic partnerships that have the potential to drive growth and create value for our shareholders while advancing our goals to deliver innovative therapies to patients."

About TLANDO
TLANDO is approved by the US FDA as a testosterone replacement therapy ("TRT") in adult males indicated for conditions associated with a deficiency or absence of endogenous testosterone: primary hypogonadism (congenital or acquired) and hypogonadotropic hypogonadism (congenital or acquired). It was developed using Lipocine's proprietary Lip'ral drug delivery technology platform.

For full prescribing information, please visit www.TLANDO.com.

About Lipocine

Lipocine is a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery to develop differentiated products. Lipocine has drug candidates in development as well as drug candidates for which we are exploring partnerships. Our drug candidates represent enablement of differentiated, patient friendly oral delivery options for favorable benefit to risk profile which target large addressable markets with significant unmet medical needs. 

Lipocine's clinical development candidates include: LPCN 1154, oral brexanolone, for the potential treatment of postpartum depression, LPCN 2101 for the potential treatment of epilepsy, LPCN 2203 an oral candidate targeted for the management of essential tremor, LPCN 2401 an oral proprietary combination of anabolic androgen receptor agonist and α-tocopherol, an antioxidant, as an adjunct therapy to incretin mimetics, as an aid for improved body composition in chronic weight management and LPCN 1148, a novel androgen receptor agonist prodrug for oral administration targeted for the management of symptoms associated with liver cirrhosis. Lipocine is exploring partnering opportunities for LPCN 1107, our candidate for prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, LPCN 2401 for chronic weight management, LPCN 1148, for the management of decompensated cirrhosis, and LPCN 1144, our candidate for treatment of non-cirrhotic NASH. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate developed by Lipocine, is approved by the FDA for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism, in adult males. For more information, please visit www.lipocine.com.

Forward-Looking Statements

This release contains "forward-looking statements" that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include statements that are not historical facts regarding our product development efforts, our strategic plans for developing products, our ability to monetize product candidates, including through entering into partnering arrangements, our product candidates and related clinical trials, the achievement of milestones within and completion of clinical trials, the timing and completion of regulatory reviews, outcomes of clinical trials of our product candidates, and the potential uses and benefits of our product candidates. Investors are cautioned that all such forward-looking statements involve risks and uncertainties, including, without limitation, the risks that we may not be successful in developing product candidates, we may not have sufficient capital to complete the development processes for our product candidates, we may not be able to enter into partnerships or other strategic relationships to monetize our non-core assets, the FDA will not approve any of our products, risks related to our products, expected product benefits not being realized, clinical and regulatory expectations and plans not being realized, new regulatory developments and requirements, risks related to the FDA approval process including the receipt of regulatory approvals, and our ability to utilize a streamlined approval pathway for LPCN 1154, the results and timing of clinical trials, patient acceptance of Lipocine's products, the manufacturing and commercialization of Lipocine's products, and other risks detailed in Lipocine's filings with the SEC, including, without limitation, its Form 10-K and other reports on Forms 8-K and 10-Q, all of which can be obtained on the SEC website at www.sec.gov. Lipocine assumes no obligation to update or revise publicly any forward-looking statements contained in this release, except as required by law.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/lipocine-announces-distribution-and-license-agreement-with-spc-korea-to-commercialize-tlando-in-south-korea-302292252.html

SOURCE Lipocine Inc.

FAQ

What is the new licensing agreement announced by Lipocine (LPCN) for TLANDO?

Lipocine announced a license, development and supply agreement with SPC Korea for exclusive marketing rights of TLANDO in South Korea, including upfront payment, milestone payments, and royalties.

What are the financial terms of Lipocine's (LPCN) TLANDO agreement with SPC Korea?

The agreement includes an upfront payment, regulatory and sales milestone payments, royalties on net commercial sales, and a supply price arrangement, though specific financial terms were not disclosed.

Who will handle regulatory approval for TLANDO in South Korea under Lipocine's (LPCN) new agreement?

SPC Korea will assume responsibility for obtaining regulatory approval for TLANDO within South Korea.

Lipocine Inc.

NASDAQ:LPCN

LPCN Rankings

LPCN Latest News

LPCN Stock Data

27.16M
5.19M
2.91%
9.96%
2.01%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SALT LAKE CITY